67
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Pre-eclampsia and offspring cardiovascular health: mechanistic insights from experimental studies

      review-article
      * , * , , * , * , , , *
      Clinical Science (London, England : 1979)
      Portland Press Ltd.
      blood pressure, cardiovascular disease, in utero, offspring, pre-eclampsia, pregnancy, vascular function, BP, blood pressure, BMI, body mass index, CYP, cytochrome P450, eNOS, endothelial NO synthase, HUVEC, human umbilical vein endothelial cell, IMT, intima-media thickness, I/R, ischaemia/reperfusion, IUGR, intra-uterine growth restriction, L-NAME, NG-nitro-L-arginine methyl ester, LV, left ventricular, LVH, LV hypertrophy, MMP, matrix metalloproteinase, PlGF, placental growth factor, PKCϵ, protein kinase Cϵ, ROS, reactive oxygen species, RUPP, reduced uterine artery perfusion, SBP, systolic BP, sEng, soluble endoglin, sFlt-1, soluble fms-like tyrosine kinase-1, TGF, transforming growth factor, TIMP, tissue inhibitor of metalloproteinases, VEGF, vascular endothelial growth factor

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Pre-eclampsia is increasingly recognized as more than an isolated disease of pregnancy. Women who have had a pregnancy complicated by pre-eclampsia have a 4-fold increased risk of later cardiovascular disease. Intriguingly, the offspring of affected pregnancies also have an increased risk of higher blood pressure and almost double the risk of stroke in later life. Experimental approaches to identify the key features of pre-eclampsia responsible for this programming of offspring cardiovascular health, or the key biological pathways modified in the offspring, have the potential to highlight novel targets for early primary prevention strategies. As pre-eclampsia occurs in 2–5% of all pregnancies, the findings are relevant to the current healthcare of up to 3 million people in the U.K. and 15 million people in the U.S.A. In the present paper, we review the current literature that concerns potential mechanisms for adverse cardiovascular programming in offspring exposed to pre-eclampsia, considering two major areas of investigation: first, experimental models that mimic features of the in utero environment characteristic of pre-eclampsia, and secondly, how, in humans, offspring cardiovascular phenotype is altered after exposure to pre-eclampsia. We compare and contrast the findings from these two bodies of work to develop insights into the likely key pathways of relevance. The present review and analysis highlights the pivotal role of long-term changes in vascular function and identifies areas of growing interest, specifically, response to hypoxia, immune modification, epigenetics and the anti-angiogenic in utero milieu.

          Related collections

          Most cited references187

          • Record: found
          • Abstract: found
          • Article: not found

          Oxidative stress shortens telomeres.

          Telomeres in most human cells shorten with each round of DNA replication, because they lack the enzyme telomerase. This is not, however, the only determinant of the rate of loss of telomeric DNA. Oxidative damage is repaired less well in telomeric DNA than elsewhere in the chromosome, and oxidative stress accelerates telomere loss, whereas antioxidants decelerate it. I suggest here that oxidative stress is an important modulator of telomere loss and that telomere-driven replicative senescence is primarily a stress response. This might have evolved to block the growth of cells that have been exposed to a high risk of mutation.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Circulating angiogenic factors and the risk of preeclampsia.

            The cause of preeclampsia remains unclear. Limited data suggest that excess circulating soluble fms-like tyrosine kinase 1 (sFlt-1), which binds placental growth factor (PlGF) and vascular endothelial growth factor (VEGF), may have a pathogenic role. We performed a nested case-control study within the Calcium for Preeclampsia Prevention trial, which involved healthy nulliparous women. Each woman with preeclampsia was matched to one normotensive control. A total of 120 pairs of women were randomly chosen. Serum concentrations of angiogenic factors (total sFlt-1, free PlGF, and free VEGF) were measured throughout pregnancy; there were a total of 655 serum specimens. The data were analyzed cross-sectionally within intervals of gestational age and according to the time before the onset of preeclampsia. During the last two months of pregnancy in the normotensive controls, the level of sFlt-1 increased and the level of PlGF decreased. These changes occurred earlier and were more pronounced in the women in whom preeclampsia later developed. The sFlt-1 level increased beginning approximately five weeks before the onset of preeclampsia. At the onset of clinical disease, the mean serum level in the women with preeclampsia was 4382 pg per milliliter, as compared with 1643 pg per milliliter in controls with fetuses of similar gestational age (P<0.001). The PlGF levels were significantly lower in the women who later had preeclampsia than in the controls beginning at 13 to 16 weeks of gestation (mean, 90 pg per milliliter vs. 142 pg per milliliter, P=0.01), with the greatest difference occurring during the weeks before the onset of preeclampsia, coincident with the increase in the sFlt-1 level. Alterations in the levels of sFlt-1 and free PlGF were greater in women with an earlier onset of preeclampsia and in women in whom preeclampsia was associated with a small-for-gestational-age infant. Increased levels of sFlt-1 and reduced levels of PlGF predict the subsequent development of preeclampsia. Copyright 2004 Massachusetts Medical Society
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Fetal origins of coronary heart disease.

              The fetal origins hypothesis states that fetal undernutrition in middle to late gestation, which leads to disproportionate fetal growth, programmes later coronary heart disease. Animal studies have shown that undernutrition before birth programmes persisting changes in a range of metabolic, physiological, and structural parameters. Studies in humans have shown that men and women whose birth weights were at the lower end of the normal range, who were thin or short at birth, or who were small in relation to placental size have increased rates of coronary heart disease. We are beginning to understand something of the mechanisms underlying these associations. The programming of blood pressure, insulin responses to glucose, cholesterol metabolism, blood coagulation, and hormonal settings are all areas of active research.
                Bookmark

                Author and article information

                Journal
                Clin Sci (Lond)
                Clin. Sci
                cls
                CS
                Clinical Science (London, England : 1979)
                Portland Press Ltd.
                0143-5221
                1470-8736
                23 March 2012
                1 July 2012
                : 123
                : Pt 2
                : 53-72
                Affiliations
                *Oxford Cardiovascular Clinical Research Facility, Department of Cardiovascular Medicine, University of Oxford, Oxford, U.K.
                †Wellcome Trust Centre for Human Genetics, Department of Cardiovascular Medicine, University of Oxford, Oxford, U.K.
                ‡Nuffield Department of Obstetrics and Gynaecology, University of Oxford, Oxford, U.K.
                Author notes
                Correspondence: Dr Paul Leeson (email paul.leeson@ 123456cardiov.ox.ac.uk ).
                Article
                CS20110627
                10.1042/CS20110627
                3315178
                22455350
                e493a190-27fa-4f90-b1b9-c9dc51ca14c4
                © 2012 The Author(s) The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/) which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.

                This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

                History
                : 5 December 2011
                : 30 January 2012
                : 10 February 2012
                Page count
                Figures: 4, Tables: 1, References: 208, Pages: 20
                Categories
                Review Article
                S1
                S9

                Medicine
                timp, tissue inhibitor of metalloproteinases,vascular function,vegf, vascular endothelial growth factor,sbp, systolic bp,rupp, reduced uterine artery perfusion,bmi, body mass index,pre-eclampsia,pregnancy,l-name, ng-nitro-l-arginine methyl ester,lvh, lv hypertrophy,offspring,enos, endothelial no synthase,iugr, intra-uterine growth restriction,lv, left ventricular,bp, blood pressure,tgf, transforming growth factor,pkcϵ, protein kinase cϵ,huvec, human umbilical vein endothelial cell,blood pressure,sflt-1, soluble fms-like tyrosine kinase-1,i/r, ischaemia/reperfusion,seng, soluble endoglin,cyp, cytochrome p450,plgf, placental growth factor,mmp, matrix metalloproteinase,in utero,imt, intima-media thickness,ros, reactive oxygen species,cardiovascular disease

                Comments

                Comment on this article